Aspen Neuroscience (ASPE) investor relations material

Company overview and business model

• Clinical-stage regenerative medicine biotech developing autologous iPSC-derived therapies for CNS diseases; lead candidate sasineprocel is a single-dose cell replacement therapy for Parkinson’s disease (PD).

• Sasineprocel is designed to replace lost dopamine neurons with dopaminergic neuron precursor cells, supporting cell engraftment and restoration of dopamine signaling without long-term immunosuppression.

• An integrated iPSC platform combines patient skin biopsy, reprogramming, differentiation, automated manufacturing and genomic quality controls; planned modular capacity is hundreds of patients annually per module.

• Pipeline includes sasineprocel for sporadic and genetic PD and gene-edited autologous microglia for pediatric leukodystrophies; worldwide commercial rights are held across programs.

Financial performance and metrics

• Net loss was $62.1M in FY2025 vs. $48.6M in FY2024; H1 2026 net loss was $36.5M vs. $31.8M in H1 2025.

• FY2025 R&D expense was $41.8M vs. $35.6M in FY2024; H1 2026 R&D expense was $28.5M vs. $20.8M in H1 2025, largely tied to sasineprocel development and production.

• Cash, cash equivalents and marketable securities were $72.4M at June 30, 2026; accumulated deficit was $264.9M, and net cash used in operations was $34.5M in H1 2026.

• No product-sales revenue has been generated; substantial doubt about continued operations was cited because June 30, 2026 resources were insufficient for the following 12 months without financing.

Use of proceeds and capital allocation

• Net proceeds, together with existing cash and investments, are intended to fund the Phase 1/2a ASPIRO trial, initiate a Phase 3 sasineprocel trial, advance microglia programs toward IND-enabling studies, and cover working capital and general purposes.

• Proceeds and existing resources are not expected to complete ASPIRO, the Phase 3 trial or broader candidate development; additional capital will be needed to advance trials, pursue approvals and prepare for commercialization.

• Potential uses also include in-licensing, acquiring or investing in complementary businesses, technologies, products or assets; no current commitments were identified for these activities.